At Anthony Nolan, believe every blood cancer patient deserves the best possible chance of receiving a successful stem cell transplant.
That’s why our Destination: Cure report calls for Government support and investment in lifesaving scientific research into the factors that affect transplant outcomes.
On 25th November 2015 Chancellor George Osborne will set out the Government’s spending plans for the next five years, which will include £20 billion in cuts to departmental budgets.
We rely on Government support and investment in the UK life sciences industry, and it is our job to ensure that investment is protected so we can continue our lifesaving work.
That’s why yesterday our Chief Executive Henny Braund joined nearly 200 other companies, organisations and charities to call on the UK government to make good on its promise to make investment in science a priority during this Parliament.
Samples in our labs
In an open letter published in the Financial Times we made the case for continued support for UK science, so that organisations like ours can continue to deliver ground-breaking research that will benefit patients and save lives.
Read the full text of the letter below, and join our campaign to make sure that Government takes action to save and improve the lives of every person in need of a stem cell transplant at www.anthonynolan.org/destinationcure
Sir, The UK is a scientific superpower. Strong, predictable and long-term government investment provides the foundation for its outstanding, multidisciplinary research base. Diverse public funding is critical to maintain the UK’s world-leading position, and improve the health and wellbeing of the population. It drives growth and attracts a wealth of global corporations, investors and charities.
As representatives of almost 200 organisations from across the life sciences, we urge the government to reinforce its commitment to science in the 2015 Spending Review and cement the UK as a global leader in research and development. Our investment and support depend on it.
The UK pharmaceutical, biotechnology, medical technology and diagnostics sectors generate an estimated annual turnover of £56bn, and employ 183,000 people, even more in supply chains. Venture capitalists and specialist investors back early-stage innovative companies as they grow and flourish. Medical research charities attract support from millions of individual donors, investing £1.3bn a year and funding the salaries of more than 12,000 researchers in universities and institutes. None of this would be possible without strong government support.
Securing public funding for cross-disciplinary research will deliver benefits to patients, increase private sector confidence and deliver productivity gains, not least through the development and retention of a highly skilled workforce. In recent years, Chancellor George Osborne has made it clear that science is a personal priority. We ask the government to deliver its vision for this area by protecting its essential investment.